Vaccine Hesitancy in College Students
Abstract
:1. Introduction
1.1. Vaccine Hesitancy
1.2. Impact of COVID-19
1.3. COVID-19 Impact on College Students
1.4. Vaccine Hesitancy in College Students
1.5. Strategies for Effective Communication on Vaccination
2. Materials and Methods
2.1. Data Analysis
2.1.1. Quantitative Analysis
2.1.2. Qualitative Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Appendix A.1. The FREQ Procedure, Student by Age
Student (Student Status) | Age | ||
---|---|---|---|
Frequency | 18–26 | 27 and Older | Total |
Undergraduate | 124 | 8 | 132 |
Graduate | 80 | 99 | 179 |
Total | 204 | 107 | 311 |
Statistic | DF | Value | Prob |
---|---|---|---|
Chi-Square | 1 | 81.6445 | <0.0001 |
Likelihood Ratio Chi-Square | 1 | 93.8879 | <0.0001 |
Continuity Adj. Chi-Square | 1 | 79.4769 | <0.0001 |
Mantel–Haenszel Chi-Square | 1 | 81.3820 | <0.0001 |
Phi Coefficient | 0.5124 | ||
Contingency Coefficient | 0.4560 | ||
Cramer’s V | 0.5124 |
n | % | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | ||
Undergraduate | 18–26 | 36 | 16 | 9 | 63 | 124 | 29 | 13 | 7 | 51 | 100 |
27 and older | 6 | 1 | 1 | . | 8 | 75 | 13 | 13 | . | 100 | |
Total | 42 | 17 | 10 | 63 | 132 | 32 | 13 | 8 | 48 | 100 | |
Graduate | 18–26 | 8 | 2 | 9 | 61 | 80 | 10 | 3 | 11 | 76 | 100 |
27 and older | 4 | 2 | 7 | 86 | 99 | 4 | 2 | 7 | 87 | 100 | |
Total | 12 | 4 | 16 | 147 | 179 | 7 | 2 | 9 | 82 | 100 | |
Total | 18–26 | 44 | 18 | 18 | 124 | 204 | 22 | 9 | 9 | 61 | 100 |
27 and older | 10 | 3 | 8 | 86 | 107 | 9 | 3 | 7 | 80 | 100 | |
Total | 54 | 21 | 26 | 210 | 311 | 17 | 7 | 8 | 68 | 100 |
Criterion | Value/DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq | |||
---|---|---|---|---|---|---|---|---|
Deviance | 1.7308 | Likelihood Ratio | <0.0001 | Age | 0.0875 | |||
. | . | Student | <0.0001 | |||||
. | . | Age student | 0.0004 | |||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | |||||||
Student Status | Age | 27 and older | No | No, or will wait | No, will wait, or will receive | |||
Undergraduate | 18–26 | 0.11(0.002) | 27.9% ± 3.8% | 38.8% ± 4.3% | 51.1% ± 4.5% | |||
27 and older | 77.2% ± 14% | 84.7% ± 10% | 90.2% ± 7.1% | |||||
Graduate | 18–26 | 2.06(0.065) | 10.1% ± 2.6% | 15.5% ± 3.6% | 23.3% ± 4.6% | |||
27 and older | 5.2% ± 1.6% | 8.2% ± 2.3% | 12.9% ± 3.3% |
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
American Indian or Alaska Native | 2 | 0 | 0 | 3 | 5 | 40 | 0 | 0 | 60 | 100 |
Asian | 0 | 3 | 9 | 45 | 57 | 0 | 5 | 16 | 79 | 100 |
Black or African American | 1 | 0 | 0 | 14 | 15 | 7 | 0 | 0 | 93 | 100 |
Hispanic or Latino | 1 | 4 | 5 | 19 | 29 | 3 | 14 | 17 | 66 | 100 |
Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | . | . | . | . | . |
White | 48 | 14 | 13 | 135 | 210 | 23 | 7 | 6 | 64 | 100 |
Total | 52 | 21 | 27 | 216 | 316 | 16 | 7 | 9 | 68 | 100 |
Criterion | Value/DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq |
---|---|---|---|---|---|
Deviance | 1.8682 | Likelihood Ratio | 0.0025 | q2_1 | 0.8744 |
. | . | q2_2 | 0.0078 | ||
. | . | q2_3 | 0.0024 | ||
. | . | q2_4 | 0.0761 | ||
. | . | q2_6 | 0.1219 |
Appendix A.2. The FREQ Procedure by Annual Influenza Vaccine
Student (Student Status) | Flu_vx (Annual Influenza VX) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Frequency | No | Yes | Total | |||||||
Undergraduate | 92 | 39 | 131 | |||||||
Graduate | 86 | 87 | 173 | |||||||
Total | 178 | 126 | 304 | |||||||
Frequency Missing = 7 | ||||||||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | |||||||||
Race | Asian | Black or African American | Hispanic or Latino | White | No | No, or will wait | No, will wait, or will receive | |||
American Indian or Alaska Native | 11.49 (0.045) | 36.98 (0.016) | 4.58 (0.191) | 4.33 (0.204) | 52.5% ± 28% | 63.5% ± 26% | 73.1% ± 22% | |||
Asian | 3.22 (0.220) | 0.40 (0.079) | 0.38 (0.003) | 8.8% ± 2.7% | 13.2% ± 3.7% | 19.1% ± 4.9% | ||||
Black or African American | 0.12 (0.023) | 0.12 (0.007) | 2.9% ± 2.9% | 4.5% ± 4.5% | 6.8% ± 6.6% | |||||
Hispanic or Latino | 0.94 (0.895) | 19.4% ± 6.5% | 27.5% ± 8.2% | 37.2% ± 9.5% | ||||||
White | 20.3% ± 2.8% | 28.7% ± 3.2% | 38.6% ± 3.5% |
Student (Student Status) | Flu_vx (Annual Influenza VX) | ||
---|---|---|---|
Frequency | No | Yes | Total |
Undergraduate | 92 | 39 | 131 |
Graduate | 86 | 87 | 173 |
Total | 178 | 126 | 304 |
Frequency Missing = 7 |
Table of Age by Flu_vx | |||
---|---|---|---|
Age | Flu_vx (Annual Influenza VX) | ||
Frequency | No | Yes | Total |
18–26 | 126 | 73 | 199 |
27 and older | 52 | 53 | 105 |
Total | 178 | 126 | 304 |
Frequency Missing = 7 |
Statistic | DF | Value | Prob |
---|---|---|---|
Chi-Square | 1 | 5.3880 | 0.0203 |
Likelihood Ratio Chi-Square | 1 | 5.3583 | 0.0206 |
Continuity Adj. Chi-Square | 1 | 4.8347 | 0.0279 |
Mantel–Haenszel Chi-Square | 1 | 5.3703 | 0.0205 |
Phi Coefficient | 0.1331 | ||
Contingency Coefficient | 0.1320 | ||
Cramer’s V | 0.1331 |
Appendix A.3. Summary Statistics
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
No | 47 | 16 | 10 | 105 | 178 | 26 | 9 | 6 | 59 | 100 |
Yes | 7 | 5 | 15 | 99 | 126 | 6 | 4 | 12 | 79 | 100 |
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 |
Deviance and Pearson Goodness-of-Fit Statistics | ||||
---|---|---|---|---|
Criterion | Value | DF | Value/DF | Pr > ChiSq |
Deviance | 12.8902 | 2 | 6.4451 | 0.0016 |
Pearson | 13.5442 | 2 | 6.7721 | 0.0011 |
n | % | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |||
Undergraduate | 18–26 | No | 34 | 12 | 4 | 34 | 84 | 40 | 14 | 5 | 40 | 100 |
Yes | 2 | 4 | 4 | 29 | 39 | 5 | 10 | 10 | 74 | 100 | ||
Total | 36 | 16 | 8 | 63 | 123 | 29 | 13 | 7 | 51 | 100 | ||
27 and older | No | 6 | 1 | 1 | . | 8 | 75 | 13 | 13 | . | 100 | |
Total | 6 | 1 | 1 | . | 8 | 75 | 13 | 13 | . | 100 | ||
Total | No | 40 | 13 | 5 | 34 | 92 | 43 | 14 | 5 | 37 | 100 | |
Yes | 2 | 4 | 4 | 29 | 39 | 5 | 10 | 10 | 74 | 100 | ||
Total | 42 | 17 | 9 | 63 | 131 | 32 | 13 | 7 | 48 | 100 | ||
Graduate | 18–26 | No | 6 | 1 | 3 | 32 | 42 | 14 | 2 | 7 | 76 | 100 |
Yes | 2 | 1 | 6 | 25 | 34 | 6 | 3 | 18 | 74 | 100 | ||
Total | 8 | 2 | 9 | 57 | 76 | 11 | 3 | 12 | 75 | 100 | ||
27 and older | No | 1 | 2 | 2 | 39 | 44 | 2 | 5 | 5 | 89 | 100 | |
Yes | 3 | . | 5 | 45 | 53 | 6 | . | 9 | 85 | 100 | ||
Total | 4 | 2 | 7 | 84 | 97 | 4 | 2 | 7 | 87 | 100 | ||
Total | No | 7 | 3 | 5 | 71 | 86 | 8 | 3 | 6 | 83 | 100 | |
Yes | 5 | 1 | 11 | 70 | 87 | 6 | 1 | 13 | 80 | 100 | ||
Total | 12 | 4 | 16 | 141 | 173 | 7 | 2 | 9 | 82 | 100 | ||
Total | 18–26 | No | 40 | 13 | 7 | 66 | 126 | 32 | 10 | 6 | 52 | 100 |
Yes | 4 | 5 | 10 | 54 | 73 | 5 | 7 | 14 | 74 | 100 | ||
Total | 44 | 18 | 17 | 120 | 199 | 22 | 9 | 9 | 60 | 100 | ||
27 and older | No | 7 | 3 | 3 | 39 | 52 | 13 | 6 | 6 | 75 | 100 | |
Yes | 3 | . | 5 | 45 | 53 | 6 | . | 9 | 85 | 100 | ||
Total | 10 | 3 | 8 | 84 | 105 | 10 | 3 | 8 | 80 | 100 | ||
Total | No | 47 | 16 | 10 | 105 | 178 | 26 | 9 | 6 | 59 | 100 | |
Yes | 7 | 5 | 15 | 99 | 126 | 6 | 4 | 12 | 79 | 100 | ||
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 |
Criterion | Value/DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq | |||
---|---|---|---|---|---|---|---|---|
Deviance | 1.8816 | Likelihood Ratio | <0.0001 | Student | <0.0001 | |||
. | . | Age | 0.2587 | |||||
. | . | Flu_vx | 0.0669 | |||||
. | . | Age student | 0.0048 | |||||
. | . | Student Flu_vx | 0.0119 | |||||
. | . | Age Flu_vx | 0.6824 | |||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | |||||||
Student Status | Age | Annual Influenza VX | No | No | No, or will wait | No, will wait, or will receive | ||
Undergraduate | 18–26 | Yes | 0.18(<0.001) | 10.1% ± 3.5% | 16.2% ± 5.0% | 24.5% ± 6.7% | ||
No | 38.0% ± 5.1% | 51.3% ± 5.4% | 64.0% ± 5.1% | |||||
27 and older | No | 77.0% ± 14% | 85.2% ± 10% | 90.6% ± 6.8% | ||||
Graduate | 18–26 | Yes | 0.99(0.979) | 10.0% ± 3.6% | 16.1% ± 5.2% | 24.4% ± 7.0% | ||
No | 10.2% ± 3.5% | 16.3% ± 5.1% | 24.7% ± 6.7% | |||||
27 and older | Yes | 1.37(0.603) | 5.6% ± 2.2% | 9.3% ± 3.3% | 14.7% ± 4.8% | |||
No | 4.2% ± 2.0% | 7.0% ± 3.1% | 11.2% ± 4.7% |
n | % | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | ||||||
No | 41 | 18 | 21 | 180 | 260 | 16 | 7 | 8 | 69 | 100 | |||||
Yes | 13 | 3 | 4 | 24 | 44 | 30 | 7 | 9 | 55 | 100 | |||||
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 | |||||
Criterion | Value/DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq | ||||||||||
Deviance | 0.2364 | Likelihood Ratio | 0.0377 | test | 0.0377 | ||||||||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | ||||||||||||||
COVID-19 Positive | No | No | No, or will wait | No, will wait, or will receive | |||||||||||
Yes | 1.97(0.038) | 27.5% ± 6.0% | 36.7% ± 6.9% | 46.5% ± 7.3% | |||||||||||
No | 16.2% ± 2.2% | 22.7% ± 2.5% | 30.6% ± 2.8% |
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
News | 26 | 13 | 10 | 104 | 153 | 17 | 8 | 7 | 68 | 100 |
Peer-reviewed articles | 27 | 8 | 16 | 96 | 147 | 18 | 5 | 11 | 65 | 100 |
Social media | 10 | 7 | 3 | 43 | 63 | 16 | 11 | 5 | 68 | 100 |
Family and/or friends | 25 | 7 | 9 | 98 | 139 | 18 | 5 | 6 | 71 | 100 |
Healthcare provider | 26 | 6 | 8 | 81 | 121 | 21 | 5 | 7 | 67 | 100 |
Other | 4 | 1 | 2 | 17 | 24 | 17 | 4 | 8 | 71 | 100 |
Total | 118 | 42 | 48 | 439 | 647 | 18 | 6 | 7 | 68 | 100 |
Criterion | Value/DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Deviance | 0.8866 | Likelihood Ratio | 0.9557 | q7_1 | 0.7372 | ||||||
. | . | q7_2 | 0.8278 | ||||||||
. | . | q7_3 | 0.9796 | ||||||||
. | . | q7_4 | 0.3329 | ||||||||
. | . | q7_5 | 0.7519 | ||||||||
. | . | q7_6 | 0.5487 | ||||||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | ||||||||||
Source of Information | Peer-reviewed articles | Social media | Family and/or friends | Healthcare provider | Other | No | No, or will wait | No, will wait, or will receive | |||
News | 0.87(0.684) | 0.91(0.838) | 1.18(0.650) | 0.85(0.644) | 1.22(0.688) | 18.2% ± 4.2% | 25.3% ± 5.2% | 33.6% ± 6.1% | |||
Peer-reviewed articles | 1.05(0.915) | 1.35(0.353) | 0.98(0.945) | 1.40(0.507) | 20.4% ± 4.3% | 28.0% ± 5.2% | 36.8% ± 5.9% | ||||
Social media | 1.29(0.575) | 0.93(0.867) | 1.34(0.604) | 19.6% ± 6.8% | 27.1% ± 8.5% | 35.8% ± 9.8% | |||||
Family and/or friends | 0.72(0.359) | 1.04(0.942) | 15.9% ± 3.9% | 22.3% ± 4.9% | 30.1% ± 5.8% | ||||||
Healthcare provider | 1.44(0.487) | 20.8% ± 5.1% | 28.5% ± 6.2% | 37.4% ± 7.0% | |||||||
Other | 15.4% ± 6.1% | 21.7% ± 7.9% | 29.4% ± 9.5% |
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
Self | 4 | 2 | 3 | 17 | 26 | 15 | 8 | 12 | 65 | 100 |
Someone close | 15 | 7 | 8 | 74 | 104 | 14 | 7 | 8 | 71 | 100 |
Someone close died | 2 | 2 | 1 | 23 | 28 | 7 | 7 | 4 | 82 | 100 |
No negative health effect | 33 | 13 | 15 | 114 | 175 | 19 | 7 | 9 | 65 | 100 |
Total | 54 | 24 | 27 | 228 | 333 | 16 | 7 | 8 | 68 | 100 |
Criterion | Value/ DF | Global Test | Pr > Chi-Square | Type 3 Test | Pr > ChiSq | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Deviance | 1.3697 | Likelihood Ratio | 0.2380 | q9_1 | 0.8769 | ||||||
. | . | q9_2 | 0.4295 | ||||||||
. | . | q9_3 | 0.0907 | ||||||||
Cumulative Odds Ratio (p-value) Comp. to | Cumulative Rate of VX Hesitancy ± SE | ||||||||||
Negative health impact | Someone close | Someone close died | No negative health effect | No | No, or will wait | No, will wait, or will receive | |||||
Self | 1.31 (0.596) | 2.41 (0.182) | 1.07 (0.877) | 20.6% ± 7.0% | 28.3% ± 8.5% | 37.3% ± 9.8% | |||||
Someone close | 1.83 (0.316) | 0.81 (0.429) | 16.5% ± 3.4% | 23.1% ± 4.2% | 31.1% ± 4.9% | ||||||
Someone close died | 0.44(0.091) | 9.7% ± 4.7% | 14.1% ± 6.4% | 19.8% ± 8.3% | |||||||
No negative health effect | 19.6% ± 2.7% | 27.0% ± 3.2% | 35.7% ± 3.5% |
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
Not Confident | 41 | 5 | 1 | 9 | 56 | 73 | 9 | 2 | 16 | 100 |
Undecided | 9 | 8 | 2 | 35 | 54 | 17 | 15 | 4 | 65 | 100 |
Confident | 4 | 8 | 22 | 160 | 194 | 2 | 4 | 11 | 82 | 100 |
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 |
Statistic | Value | SE |
---|---|---|
Kendall’s Tau-b | 0.5273 | 0.0473 |
Stuart’s Tau-c | 0.4088 | 0.0443 |
The Impact of Vaccine Efficacy on COVID-19 Vaccine Status (VX Status) and Hesitancy. | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
n | % | |||||||||
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
Not Confident | 33 | 5 | 1 | 9 | 48 | 69 | 10 | 2 | 19 | 100 |
Undecided | 16 | 7 | 2 | 28 | 53 | 30 | 13 | 4 | 53 | 100 |
Confident | 5 | 9 | 22 | 167 | 203 | 2 | 4 | 11 | 82 | 100 |
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 |
Statistic | Value | SE |
---|---|---|
Kendall’s Tau-b | 0.5213 | 0.0472 |
Stuart’s Tau-c | 0.3930 | 0.0431 |
n | % | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No | Will Wait | Will Receive | Have Received | Total | No | Will Wait | Will Receive | Have Received | Total | |
No | 54 | 16 | 4 | 53 | 127 | 43 | 13 | 3 | 42 | 100 |
Undecided | . | 3 | 5 | 40 | 48 | . | 6 | 10 | 83 | 100 |
Yes | . | 2 | 16 | 111 | 129 | . | 2 | 12 | 86 | 100 |
Total | 54 | 21 | 25 | 204 | 304 | 18 | 7 | 8 | 67 | 100 |
Statistic | Value | SE |
---|---|---|
Kendall’s Tau-b | 0.4525 | 0.0419 |
Stuart’s Tau-c | 0.3805 | 0.0396 |
References
- Weitz, L.; Bellach, L.; Faltum, A.; Berger, A.; Maurer, W. Vaccine hesitancy report of a student study group. Wiender Klin. Wochenschr. Cent. Eur. J. Med. 2020, 9, 243–252. [Google Scholar] [CrossRef]
- Stolle, L.B.; Nalamasu, R.; Pergolizzi, J.V.; Varrassi, G.; Magnusson, P.; LeQuang, J.; Breve, F.; NEMA Research Group. Fact vs Fallacy: The anti-vaccine discussion reloaded. Adv. Ther. 2020, 37, 4481–4490. [Google Scholar] [CrossRef]
- Ten Threats to Global Health in 2019. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed on 3 June 2022).
- MacDonald, N.E.; Butler, R.; Dubé, E. Addressing barriers to vaccine acceptance: An overview. Hum. Vaccines Immunother. 2018, 14, 218–224. [Google Scholar] [CrossRef]
- Burns, R.; Hosangadi, D.; Trotochaud, M.; Sell, T. COVID-19 Misinformation and Disinformation. Center for Health Security. 2021. Available online: https://www.centerforhealthsecurity.org/sites/default/files/2023-02/20211020-misinformation-disinformation-cost.pdf (accessed on 3 November 2022).
- Forecasts of COVID-19 Deaths. Available online: https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/forecasting-us.html (accessed on 3 November 2022).
- Silva, J.; Bratberg, J.; Lemay, V. COVID-19 and influenza vaccine hesitancy among college students. J. Am. Pharm. Assoc. 2021, 61, 709–714. [Google Scholar] [CrossRef]
- Immediate College Enrollment Rate. Available online: https://nces.ed.gov/programs/coe/indicator/cpa/immediate-college-enrollment-rate (accessed on 3 November 2022).
- Back-to-School Statistics. Available online: https://nces.ed.gov/fastfacts/display.asp?id=372 (accessed on 3 November 2022).
- Sharma, M.; Davis, R.E.; Wilkerson, A.H. COVID-19 vaccine acceptance among college students: A theory-based analysis. Int. J. Environ. Res. Public Health 2021, 18, 4617. [Google Scholar] [CrossRef]
- Ryan, K.A.; Filipp, S.L.; Gurka, M.J.; Zirulnik, A.; Thompson, L.A. Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake. Heliyon 2019, 5, E02604. [Google Scholar] [CrossRef]
- Wotring, A.; Hutchins, M.; Johnson, M.; Ferng, S.; Strawser, C.; Pfrank, H.; Warner, M.; Behrendt, L. COVID-19 Vaccine Uptake Among College Students at a Midwest University. J. Community Health 2022, 47, 292–297. [Google Scholar] [CrossRef]
- Dadaczynski, K.; Okan, O.; Messer, M.; Leung, A.Y.; Rosário, R.; Darlington, E.; Rathmann, K. Digital health literacy and web-based information seeking behaviors of university students in Germany during the COVID-19 pandemic: Cross-sectional survey study. J. Med. Internet Res. 2021, 23, e24097. [Google Scholar] [CrossRef]
- Khubchandani, J.; Biswas, N.; Mustapha, T.; Talbert, S.; Dharamsi, S. COVID-19 vaccination refusal among college students; Global trends and action priorities. Brain Behav. Immun. 2022, 99, 218–222. [Google Scholar] [CrossRef]
- Rahman, M.; Chisty, M.A.; Alam, A.; Sakib, M.S.; Quader, M.A.; Shobuj, I.A.; Halim, A.; Rahman, F. Knowledge, attitude, and hesitancy towards COVID-19 vaccine among university students of Bangladesh. PLoS ONE 2022, 17, e0270684. [Google Scholar] [CrossRef]
- Lee, J.; Huang, Y. COVID-19 Vaccine Hesitancy: The Role of Socioeconomic Factors and Spatial Effects. Vaccines 2022, 10, 352. [Google Scholar] [CrossRef]
- Benjamin, S.M.; Bahr, K.O. Barriers associated with seasonal influenza vaccination among college students. Influenza Res. Treat. 2016, 2016, 4248071. [Google Scholar] [CrossRef]
- Vergara, R.J.D.; Sarmiento, P.J.D.; Lagman, J.D.N. Building public trust: A response to COVID-19 vaccine hesitancy predicament. J. Public Health 2021, 43, e291–e292. [Google Scholar] [CrossRef]
- Ely, E.E. “The Non-Traditional Student.” Information Analyses presented at the American Association of Community Colleges Annual Conference, Anaheim, CA, April, 1997. Available online: https://eric.ed.gov/?id=ED411906 (accessed on 3 November 2022).
- Reynolds, B.L. An Investigation into the Formation of Vaccine Opinions and Attitudes in College Students. Bachelor’s Thesis, Oregon State University, Corvallis, OR, USA, 2019. [Google Scholar]
- Tuckerman, J.; Kaufman, J.; Danchin, M. Effective Approaches to Combat Vaccine Hesitancy. Pediatr. Infect. Dis. J. 2022, 41, 243–245. [Google Scholar] [CrossRef]
- Gilbert-Esparza, E. Vaccine Hesitancy in College Students. Master’s Thesis, Kansas State University, Manhattan, KS, USA, 2021. [Google Scholar]
- Carrion, M. “You need to do your research”: Vaccines, contestable science, and maternal epistemology. Public Underst. Sci. 2018, 27, 310–324. [Google Scholar] [CrossRef]
- Babb, S.J.; Rufino, K.A.; Johnson, R.M. Assessing the Effects of the COVID-19 Pandemic on Nontraditional Students’ Mental Health and Well-Being. Adult Educ. Q. 2022, 72, 140–157. [Google Scholar] [CrossRef]
- Brindis, C.; Reyes, P. At the Crossroads: Options for Financing College Health Services in the 21st Century. J. Am. Coll. Health 1997, 45, 279–288. [Google Scholar] [CrossRef]
- Elliot, L.; Yang, K. Vaccine acceptance and hesitancy among college students in Nevada: A state-wide cross-sectional study. Vaccines 2022, 10, 105. [Google Scholar] [CrossRef]
- Zhou, Y.; Ruobing, L.; Lijiang, S. Targeting COVID-19 vaccine-hesitancy in college students: An audience-centered approach. J. Am. Coll. Health [Ahead of Print]. 2023, 1–10. [Google Scholar] [CrossRef]
- Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results (accessed on 4 July 2023).
- Chu, L.; McPhee, R.; Huang, W.; Bennett, H.; Pajon, R.; Nestorova, B.; Leav, B. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021, 39, 2791–2799. [Google Scholar] [CrossRef]
- Sadoff, J.; Gray, G.; Vandebosch, A.; Cardenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 2021, 384, 2187–2201. [Google Scholar] [CrossRef]
Student Status | n | % |
---|---|---|
Undergraduate | 132 | 42.4 |
Graduate | 179 | 57.6 |
Total | 311 | 100 |
Race/Ethnicity | n | % |
White | 210 | 66.5 |
Hispanic or Latino | 29 | 9.2 |
Black or African American | 15 | 4.7 |
Asian | 57 | 18 |
American Indian or Alaska Native | 5 | 1.6 |
Hawaiian or Other Pacific Islander | 0 | 0 |
COVID Vaccination Status, n (%) | |||||
---|---|---|---|---|---|
No | Will Wait | Will Receive | Received | ||
Student Status and Age | Undergraduate 18–26 | 36 (29%) | 16 (13%) | 9 (7%) | 63 (51%) |
Undergraduate 27+ | 6 (75%) | 1 (13%) | 1 (13%) | 0 (0%) | |
Graduate 18–26 | 8 (10%) | 2 (3%) | 9 (11%) | 61 (76%) | |
Graduate 27+ | 4 (4%) | 2 (2%) | 7 (7%) | 86 (87%) | |
No | 47 (26%) | 16 (9%) | 10 (6%) | 105 (59%) | |
Yes | 7 (6%) | 5 (4%) | 15 (12%) | 99 (79%) | |
Race and Ethnicity | American Indian or Alaska Native | 2 (40%) | 0 (0%) | 0 (0%) | 3 (60%) |
Asian | 0 (0%) | 3 (5%) | 9 (16%) | 45 (79%) | |
Black or African American | 1 (7%) | 0 (0%) | 0 (0%) | 14 (93%) | |
Hispanic or Latino | 1 (3%) | 4 (14%) | 5 (17%) | 19 (66%) | |
Native Hawaiian or Other Pacific Islander | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
White | 48 (23%) | 14 (7%) | 13 (6%) | 135 (64%) | |
Influenza Vaccine Status | No | 47 (26%) | 16 (9%) | 10 (6%) | 105 (59%) |
Yes | 7 (6%) | 5 (4%) | 15 (12%) | 99 (79%) | |
COVID-19 Infection | No | 41 (16%) | 18 (7%) | 21 (8%) | 180 (69%) |
Yes | 13 (30%) | 3 (7%) | 4 (9%) | 24 (55%) | |
Negative Health Effects | Self | 4 (15%) | 2 (8%) | 3 (12%) | 17 (65%) |
Someone close | 15 (14%) | 7 (7%) | 8 (8%) | 74 (71%) | |
Someone close died | 2 (7%) | 2 (7%) | 1 (4%) | 23 (82%) | |
No negative health effect | 33 (19%) | 13 (7%) | 15 (9%) | 114 (65%) | |
Vaccine Requirements | No | 54 (43%) | 16 (13%) | 4 (3%) | 53 (42%) |
Undecided | 0 (0%) | 3 (6%) | 5 (10%) | 40 (83%) | |
Yes | 0 (0%) | 2 (2%) | 16 (12%) | 111 (86%) | |
Vaccine Efficacy | Not Confident | 33 (69%) | 5 (10%) | 1 (2%) | 9 (19%) |
Undecided | 16 (30%) | 7 (13%) | 2 (4%) | 28 (53%) | |
Confident | 5 (2%) | 9 (4%) | 22 (11%) | 167 (82%) | |
Vaccine Safety | Not Confident | 41 (73%) | 5 (9%) | 1 (2%) | 9 (16%) |
Undecided | 9 (17%) | 8 (15%) | 2 (4%) | 35 (65%) | |
Confident | 4 (2%) | 8 (4%) | 22 (11%) | 160 (82%) | |
Vaccine Requirements | No | 54 (43%) | 16 (13%) | 4 (3%) | 53 (42%) |
Undecided | 0 (0%) | 3 (6%) | 5 (10%) | 40 (83%) | |
Yes | 0 (0%) | 2 (2%) | 16 (12%) | 111 (86%) | |
Information Sources | News | 26 (17%) | 13 (8%) | 10 (7%) | 104 (64%) |
Peer-reviewed articles | 27 (18%) | 8 (5%) | 16 (11%) | 96 (65%) | |
Social media | 10 (16%) | 7 (11%) | 3 (5%) | 43 (68%) | |
Family and/or friends | 25 (18%) | 7 (5%) | 9 (6%) | 98 (71%) | |
Healthcare provider | 26 (21%) | 6 (5%) | 8 (7%) | 81 (67%) | |
Other | 4 (17%) | 1 (4%) | 2 (8%) | 17 (71%) |
COVID-19 Vaccine Hesitancy Themes | Frequency (# of times theme was identified) |
---|---|
Perception of not being at risk | 8 |
Mistrust | 7 |
Concern of vaccine long-term effects | 7 |
Prior COVID-19 infection | 5 |
Concern of health risks | 5 |
COVID-19 Vaccine Non-Hesitancy Themes | |
Protecting myself and others | 7 |
Moral obligation | 6 |
Work or school related | 5 |
A wish to return to normal | 5 |
Influenza Vaccine Non-Hesitancy Themes | |
Work or school related | 3 |
Protecting myself and others | 2 |
Trust in Influenza Vaccine | 2 |
Trust in research process | 2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gilbert-Esparza, E.; Brady, A.; Haas, S.; Wittstruck, H.; Miller, J.; Kang, Q.; Mulcahy, E.R. Vaccine Hesitancy in College Students. Vaccines 2023, 11, 1243. https://doi.org/10.3390/vaccines11071243
Gilbert-Esparza E, Brady A, Haas S, Wittstruck H, Miller J, Kang Q, Mulcahy ER. Vaccine Hesitancy in College Students. Vaccines. 2023; 11(7):1243. https://doi.org/10.3390/vaccines11071243
Chicago/Turabian StyleGilbert-Esparza, Emily, Amelia Brady, Sierrah Haas, Heather Wittstruck, Jennifer Miller, Qing Kang, and Ellyn R. Mulcahy. 2023. "Vaccine Hesitancy in College Students" Vaccines 11, no. 7: 1243. https://doi.org/10.3390/vaccines11071243
APA StyleGilbert-Esparza, E., Brady, A., Haas, S., Wittstruck, H., Miller, J., Kang, Q., & Mulcahy, E. R. (2023). Vaccine Hesitancy in College Students. Vaccines, 11(7), 1243. https://doi.org/10.3390/vaccines11071243